Gene Cluster Responsible for Validamycin Biosynthesis in Streptomyces hygroscopicus subsp. jinggangensis 5008

Yi Yu,¹ Linquan Bai,¹ Kazuyuki Minagawa,² Xiaohong Jian,¹ Lei Li,¹ Jialiang Li,¹ Shuangya Chen,¹ Erhu Cao,¹ Taifo Mahmud,² Heinz G. Floss,³ Xiufen Zhou,¹ and Zixin Deng¹*

Bio-X Life Science Research Center and School of Life Science & Biotechnology, Shanghai Jiaotong University, Shanghai 200030, People's Republic of China¹; College of Pharmacy, Oregon State University, Corvallis, Oregon 97331-3507²; and Department of Chemistry, University of Washington, Seattle, Washington 98195-1700³

Received 3 November 2004/Accepted 21 March 2005

A gene cluster responsible for the biosynthesis of validamycin, an aminocyclitol antibiotic widely used as a control agent for sheath blight disease of rice plants, was identified from *Streptomyces hygroscopicus* subsp. *jinggangensis* 5008 using heterologous probe *acbC*, a gene involved in the cyclization of D-sedoheptulose 7-phosphate to 2-*epi*-5-*epi*-valiolone of the acarbose biosynthetic gene cluster originated from *Actinoplanes* sp. strain SE50/110. Deletion of a 30-kb DNA fragment from this cluster in the chromosome resulted in loss of validamycin production, confirming a direct involvement of the gene cluster in the biosynthesis of this important plant protectant. A sequenced 6-kb fragment contained *valA* (an *acbC* homologue encoding a putative cyclase) as well as two additional complete open reading frames (*valB* and *valC*, encoding a putative adenyltransferase and a kinase, respectively), which are organized as an operon. The function of ValA was genetically demonstrated to be essential for validamycin production and biochemically shown to be responsible specifically for the cyclization of D-sedoheptulose 7-phosphate to 2-*epi*-5-*epi*-valiolone in vitro using the ValA protein heterologously overexpressed in *E. coli*. The information obtained should pave the way for further detailed analysis of the complete biosynthetic pathway, which would lead to a complete understanding of validamycin biosynthesis.

Filamentous gram-positive *Streptomyces* strains produce myriads of secondary metabolites with diversified structures and biological activities, including antibacterial, antifungal, antitumor, immunosuppressant, pesticidal, and herbicidal effects (5). The recently published genome sequences of *Streptomyces coelicolor* A3(2) (2) and *Streptomyces avermitilis* (20) further verified their position as a most abundant source of biosynthetic gene clusters encoding various bioactive compounds.

Streptomyces hygroscopicus subsp. jinggangensis 5008 (S. hygroscopicus 5008 or strain 5008 hereafter), isolated from the Jinggang Mountain area of China in 1974 (27), produces at least two antibiotics of agricultural importance. Jingangmycin, a weakly basic water-soluble aminocyclitol antibiotic, which was later proven to be identical to validamycin A (Fig. 1) produced by S. hygroscopicus var. limoneus IFO 12703 (13), has been widely used as a prime control reagent against sheath blight disease of rice plants and dumping-off of cucumber seedlings in China and many other eastern Asian countries. Upon treatment with validamycin, normal extension of the main hyphae is switched to an abnormal branching at the tips and further development of the growing fungi is severely repressed (23). Furthermore, voglibose, a valiolamine derivative produced from validamycin by bioconversion and chemical modifications (10), is widely used for the treatment of diabetes.

The other antibiotic, jingsimycin, is an acidic polypeptide similar to saramycetin and has activity against various fungi.

A structural comparison between validamycin A and acarbose (Fig. 1), a compound used for the treatment of type II insulin-independent diabetes, revealed that they contain an identical C_7N aminocyclitol moiety (16), valienamine, whose structure and stereochemistry resemble that of D-glucose and which is responsible for the strong inhibitory activity of acarbose against α -glucosidases. Based on feeding experiments with isotopically labeled precursors, 2-*epi*-5-*epi*-valiolone, 5-*epi*-valiolone, valienone, and validone were suggested to be the intermediates of the validamycin A biosynthetic pathway by Floss and coworkers (7) (Fig. 1).

The incorporation patterns of various putative intermediates seemed to be different between the validamycin-producing S. hygroscopicus var. limoneus and the acarbose-producing Actinoplanes sp. strain SE50/110, but 2-epi-5-epi-valionone was found to be efficiently incorporated into both compounds, suggesting that both biosynthetic pathways share the same initial cyclization reaction catalyzed by common enzymes with similar activities. AcbC, an enzyme closely related to 3-dehydroquinate synthetases (AroB proteins), was proven to be involved in the cyclization of D-sedoheptulose 7-phosphate to 2-epi-5-epi-valionone in acarbose biosynthesis (25). The encoding gene (acbC) was thus used as a heterologous probe for the cloning of the validamycin biosynthetic genes from S. hygroscopicus 5008, which is reported in this paper. The direct involvement of valA, an acbC homologue, in validamycin biosynthesis was confirmed in vivo by gene inactivation as well as in

^{*} Corresponding author. Mailing address: Bio-X Life Science Research Center, Shanghai Jiaotong University, Shanghai 200030, China. Phone: 86 21 62933404. Fax: 86 21 62932418. E-mail: zxdeng@sjtu .edu.cn.



FIG. 1. Chemical structures of acarbose and validamycin A (top), and the initial intermediates proposed to be involved in validamycin A biosynthesis (bottom) (7). Boxed regions show the valienamine moiety shared by both compounds.

vitro by biochemical characterization of the reaction catalyzed by the ValA protein heterologously overexpressed in *E. coli*.

MATERIALS AND METHODS

Bacterial strains, phage, plasmids, and cosmids. Bacterial strains, phage, plasmids, and cosmids are described in Table 1.

Culture techniques, transformation, and conjugation. *S. hygroscopicus* 5008 and its derivatives were grown on SFM agar plates or in TSB liquid medium supplemented with 10.3% (wt/vol) sucrose and 1% (wt/vol) yeast extract (15) at 28°C for growth of mycelia, isolation of total DNA, or conjugation. FM-II liquid medium (containing [per liter] soluble starch, 60 g; sucrose, 30 g; beef extract, 35 g; NaCl, 0.75 g; MgSO₄ 2 g; CaCO₃ 8 g; initial pH, 7.8.) was used for fermentation. Protoplast preparation and transformation were performed according to Hopwood et al. (9). *Escherichia coli* strains were cultured according to Sambrook et al. (22). Cosmid clones were selected after infection of *E. coli* LE392 on LB agar containing 100 μ g ampicillin ml⁻¹ or 30 μ g apramycin ml⁻¹. For selection of *Streptomyces* transformants, apramycin and thiostrepton were both used at 30 μ g ml⁻¹ in SFM agar medium and at 5 μ g ml⁻¹ in liquid media.

Cloning techniques. Plasmid and total DNA was isolated from *Streptomyces* strains according to Kieser et al. (15). Restriction enzymes, T4 DNA ligase, *Taq* polymerase, and alkaline phosphatase were purchased from various companies (New England Biolabs, Takara, and MBI Fermentas). The gel recovery kit (Shanghai Watson and QIAGEN) was used for DNA recovery from agarose gels. For the generation of cosmid libraries, total DNA samples were partially digested with MboI, dephosphorylated with calf intestinal alkaline phosphatase, and size-fractionated by sedimentation analysis using a sucrose gradient (9). DNA fragments between 30 and 40 kb were mixed in a 1:1 molar ratio with BamHI-digested cosmid vector pHZ1358 and ligated at ca. 200 μ g ml⁻¹ DNA. Packaging was done with λ packaging mixes prepared according to Sambrook et al. (22).

DNA probes, PCR primers, and Southern hybridization. An NdeI-EcoRI fragment carrying the *acbC* gene from *Actinoplanes* sp. strain SE50/110 producing acarbose was excised from plasmid pAS8/7 (25) and used as a heterologous probe. The two oligonucleotide primers used for PCR amplification were VaIA-F (5'-GGATCCACATATGACCATGACCAAG-3') and VaIA-R (5'-GAATTCA CACCCCATGTCC-3'). For Southern hybridization experiments, *S. hygroscopicus* 5008 genomic DNA was cleaved with restriction enzyme, separated on 0.8% agarose gels, and transferred onto Hybond-N⁺ nylon membrane (Amersham-Pharmacia). α -[³²P]dCTP-labeled radioactive probes using a random priming kit (Roche) were used for both Southern blots and in situ colony hybridization.

Construction of pHZ2236 for targeted deletion of 30-kb region within the ca. 70-kb contig. Complete digestion of cosmid 3G8 DNA by BamHI and religation resulted in the construction of pHZ2234, in which an internal ca. 30 kb (marked by a solid bar in Fig. 2) of 3G8 was found to be deleted and the two 2.1-kb flanking fragments were connected. Then a 1.4-kb BamHI fragment carrying aac(3)IV (apramycin resistance gene) was inserted between the two 2.1-kb fragments with the same transcriptional direction as *valA*, which generated pHZ2236 for subsequent conjugation.

Construction of pJTU519 for targeted deletion of 563 bp of DNA internal to *valA*. A 1.33-kb XbaI-EcoRI fragment overlapping one side of the *valA* gene on the ca. 6-kb sequenced BamHI fragment (Fig. 2) in pHZ2229 was excised from pJTU690 and inserted into the corresponding site of pBluescript II SK(+), resulting in pJTU504. A 1.4-kb EcoRI fragment carrying the apramycin resistance gene *aac(3)IV* was inserted into the EcoRI site of pJTU504 to generate pJTU514, which was subsequently digested with EcoRV and HindIII to accept a 1.5-kb PvuII-HindIII fragment of pJTU696 overlapping the other end of the *valA* on the ca. 6-kb sequenced BamHI fragment (Fig. 2) to generate pJTU515. A total of 4.23 kb of DNA linking 1.33 kb (left arm)-1.4 kb *aac(3)IV*-1.5 kb (right arm), was transferred as an XbaI fragment to the corresponding site of pJI2925 to construct pJTU516, for the final excision as a BgIII fragment to be inserted into the unique BamHI site of pHZ1358, resulting in pJTU519 as a final construct for the targeted replacement of a 563-bp DNA fragment internal to *valA* by the 1.4-kb *aac(3)IV*, in the wild-type strain 5008.

Antibiotic assay. Production of validamycin by S. hygroscopicus 5008 and its derivatives was detected using a bioassay and high performance liquid chromatography (HPLC). For the bioassay, 1 milliliter of fermentation supernatant extracted with chloroform was mixed with 14 ml of melted agar (8 g of agar, 1 liter of water). An agar plug with Pellicularia sasakii (Shanghai Jiaotong University Stock Collection, Shanghai Jiaotong University, Shanghai), which is sensitive to validamycin, was transferred to the center of the agar plate and after 24 h incubation at 30°C the diameter of the colony was measured, which is inversely related to the inhibitory potency. For HPLC analysis, the strains were cultured in 40 ml of FM-II fermentation medium in 250-ml baffled flasks at 37°C and 220 rpm for 6 days. The fermentation broth was centrifuged at 12,000 rpm for 5 min followed by chloroform extraction. The extracted supernatant was directly loaded onto a Nucleosil C18 column (250 mm by 4.6 mm, Sigma-Aldrich) for HPLC analysis (Waters 220). The mobile phase (0.005 M sodium phosphate buffer-acetone, 97:3) was applied with the flow rate of 1 ml min⁻¹ at room temperature. The elute was monitored at 210 nm with a Waters 996 photodiode array detector and the data were analyzed with a Waters Millennium Chromatography Manager.

Sequence analysis. DNA sequencing was done at Shanghai Sangon Ltd. using pUC18 as the vector. Sequencing reactions were carried out using the Amersham Thermosequenase sequencing kit containing fluorescent dye terminators and an Applied Biosystems model 377 automated DNA sequencer. Sequence analysis was performed with the Lasergene DNA analysis tools (DNASTAR) (Madison, MI). Open reading frames and ribosome binding sites were predicted with FramePlot (11). Nucleotide and amino acid sequence comparisons against public databases were done using the BLAST program (1).

Cloning and heterologous overexpression of recombinant His₆-tagged ValA.

Suppose 5008Wild-type producer of validamycin source of validamycin generated by gene replacement of a c. 304b region including abC homolog with $aac(3)D'$ This work (Fig. 3)Zi This work (Fig. 3)JXH-1As above, but replacing a 565-by DNA fragment internal to valdThis work (Fig. 3)JXH-1As above, but replacing a 565-by DNA fragment internal to valdThis work (Fig. 3)S. lividans 66 ZX1 $rec.46$ str-6 pro-230E. coli strains DH10B Γ merA $\Delta(mr-halRMS-merBC)$ & 804/lacZAM15 MacX74 deaR rec14 endA1 araA139 D(an, leu)1697 galU galK λ rpsL nupG amb in bitS/DU2002 ampE4 supF38 hadR514, used for infection with in vitro-packaged commids21BL2[Gold(DE3)/pLysS Γ ompT isdS/g, ($r_1^- m_1^-$) gal dem(DE3) pLysS (Cm')18SL1-I-BlueFrompT isdS/g, ($r_1^- m_1^-$) gal dem(DE3) pLysS (Cm')18Pasmids pAS8/7pL16021 with a 1.264-bp Ndel-EcoRI fragment containing acbC in the corresponding sites25PBLiceScript II SK(+) pT122229pBlueScript II SK(-) (perrying a c. 6.4b sequenced Bam111 tragment (Fig. 2) from cosmid 3C8 anac(3)/V gene trais studyThis studyp122225 pJTU504Insertion of a 1.33-kb Xbal-EcoRI fragment from pJTU690 in pBlueScript II SK(+)This studyp17U516Insertion of a 1.33-kb Xbal-EcoRI fragment from pJTU690 in the insertion of a 4.23-kb BglI fragment from pJTU690 in the insertion of a 4.23-kb BglI fragment from pJTU690 in the insertion of a 4.23-kb BglI fragment from pJTU690 in the insertion of a 4.23-kb BglI fragment from pJTU690 in the inset dive of the 6-bis sequenced Bam111 fragment (Fig. 2) including the 1.3-kb Xbal-EcoRI fragment from pJTU690 in t	Strain, phage, or plasmid	Relevant characteristics ^a	Reference or source		
5008 VU-1 VU-1Wild-type producer of validamycin Norproducer of validamycin exact 304b region including <i>acbC</i> homolog with <i>aac(3)W</i> act 304b region including <i>acbC</i> homolog with <i>aac(3)W</i> This work (Fig. 3)27 This work (Fig. 3)S. Inidans 66 ZX1rec-46 str-6 pro-230E. coll strains DF110B F^- mcrA $\Delta(mr-hsdRMS-mcrBC) \phi 80dlacZ\DeltaM15 \Delta acX74 deRrec/1 endA1 and X39 D(ant, lea)1697 galU galK \lambda^- rps1. mupGadm dem hsdSpUZ80022121212121E. 267(pUZ8002)LE392gam dem hsdSpUZ8002cosmidsrec/1 endA1 gam ZM54 micR14/1, used for infection with in vitro-packagedcosmidsrec/1 endA1 gamZM54 micR14/1, used for infection with in vitro-packagedcosmids31BL21Gold(DE3)(pLysSPF-ompT hsdSp (r_n^- m_n^-) gal dcm(DE3) pLysS (Cm+)the corresponding sites18StratageneStratagenePellicularia sasakiiFungal indicator strain sensitive to validamycin ASUUSCStratagenePlasmidsp122229p116021 with a 1.264-bp Ndel-EcoRI fragment containing acbC inthe corresponding sitesStratagene25Stratagenep1122229p112224p11204bla la corresponding sitesStratageneThis studyp12225p11204frament of a 1.3-bb Xbal-EcoRI fragment from pTU690 inp12236 (more in a cn. 6-kb sequenced BamH1p112051 (more in a cn. 6-kb sequenced BamH1p112051 (more in a cn. 6-kb sequenced BamH1p11238 (more in a cn. 6-kb sequenced BamH1p11238 (more in a cn. 6-kb sequenced BamH1p11238 (more in a cn. 6-kb sequenced BamH1p11234 (more in a cn. 6-kb sequenced BamH1p11234 (more in a cn. 6-kb sequenced BamH1p11235This studyp17U516Imsertion of a 1.3-kb X$	S. hygroscopicus strains				
YU-1Nonproducer of validamycin generated by gene replacement of a c. a. 30-kbr region including ac/C homolog with aca(3)// JXH-1This work (Fig. 3)JXH-1As above, but replacing a 563-bp DNA fragment internal to val/This work (Fig. 3)S. lividans 66 ZX1rec-46 str-6 pro-230E. coli strains $rec-46$ str-6 pro-230DH10B F^- mcr4 $\Delta(mr-hsdRMS-mcrBC)$ ϕ 80dlac ZAM15 $\Delta lac X74$ deoR rec41 entA1 anaJ39 $D(ma, lea)1697$ gall galk λ rpsl. nupGGIBCO-BRLE12567(pUZ8002)dam den hsdSbyD2800221LE392sapE44 supF58 hsdR514, used for infection with in vitro-packaged cosmids3BL2[Gold(DE3)/pLyS F^- ompT hsdSa ₀ (r_e^- m_e^-) gal dem(DE3) pLyS (Cm')18XL1-Bluefradical endAl grA96 bit-1 hsdR17 supE4 relA1 lacStratagenePellicularia saskiiFungal indicator strain sensitive to validamycin ASJUSCPlasmidspJE021 with a 1.264-bp Nde1-EcoRI fragment containing acbC in the corresponding sites25pHZ1358Cosmid used for the construction of 5008 genomic library; pJ1101 derivative; tor Life with the insertion of 30(8) sandwiched between the two 2.1-kb genomic DNA fragmentsThis studypHZ2326pBlueScript II SK(+) pJTU504pBlueScript II SK(+) pJTU504This study the cost with the insertion of aca(3)// gen sandwiched between the two 2.1-kb genomic DNA fragments12pJTU516Insertion of a 1.33-kb Xba1-EcoRI fragment from pJTU690 in pBlueScript II SK(+)This study14pJTU504Insertion of a 4.23-kb RgH fragment from pJTU690 in the t.13-3kb Xba1-EcoRI fragment from pJTU690 in	5008	Wild-type producer of validamycin	27		
JXH-1As above, but replacing a 563-bp DNA fragment internal to val/This work (Fig. 5)S. lividans 66 ZX1 $rec-46$ str-6 pro-230E. coli strains DH10B F^- mord $\Delta(mar-hadRMS-mcrBC)$ $\delta 80 klac Z\Delta M15$ $\Delta lac X74$ deoR recA1 andA1 an $\Delta 139$ $D(an, lea)1697$ gall galK χ -rpsl. mapG21LE392sapE44 sapE58 hadR514, used for infection with in vitro-packaged cosmids3BL21Gold(DE3)pLysS F^- omp7 had3 μ_s ($r_a^ m_a^-$) gal dcm(DE3) pLysS (Cm')18Pellicularia asakiiFungal indicator strain sensitive to validamycin ASUSCPlasmids pPZ2229pJ106021 with a 1.264-bp Nde1-EcoRI fragment containing acbC in the corresponding sites25pBlueScript II SK(+)bla lac Z onflStratagenePHZ21358Cosmid used for the construction of 5008 genomic library; pJ1101 drainevirt tr_{ar} at r_{ar} of r_{ar} or r_{ar} of r_{ar} mapf fragment ($Fig. 2$) from cosmid 368This study fragment ($Fig. 2$) from cosmid 368pHZ2236Insertion in BamH1 site of pHZ2324 of an acc(3)// gene sandwicked between the two 2.1-kb genomic DNA fragments12pJTU504pJTU504Insertion of a 1.33-kb Xba1-EcoRI fragment from pJTU690 in pJTU515This study the insertion of a all-kb Bull fragment from pJTU690 in pJTU516This study the insertion of a all-kb Bull fragment from pJTU690 in the insertion of a 1.33-kb Xba1-EcoRI fragment from pJTU690 in pJTU516This study the insertion of a all-kb Bull fragment from pJTU690 in the insertion of a all-kb Bull fragment from pJTU690 in the insertion of a all-kb Bull fragment from pJTU690 in the is study which contains a linked 1.33-kb (left arm)1.4kb bacc(2	YU-1	Nonproducer of validamycin generated by gene replacement of a ca. 30-kb region including <i>acbC</i> homolog with <i>aac(3)IV</i>	This work (Fig. 3)		
S. Inidans 66 ZX1rec-46 str-6 pro-230E. coli strains DH10B F^- mcrA $\Delta(mnr-hsdRMS-mcrBC) \ 680dlacZAMIS MacX74 deoRrecA1 endA1 anaM39 D(am, lea)[697 galU galK \Lambda^- rpJ. mapGGIBCO-BRLET12567(pUZ8002)dam den hsdS[pUZ8002supGF4 sup78 hsdR514, used for infection with in vitro-packagedcosmids21LE392supGF4 sup78 hsdR514, used for infection with in vitro-packagedcosmids3BL21Gold(DE3)[pLysSF^- ompT hsdS_n (r_m^- m_m^-) gal dcm(DE3) pLysS (Cm')recA1 endA1 grx196 thi-1 hsdR17 supE44 relA1 lacStratagenePellicularia sasakiiFungal indicator strain sensitive to validamycin ASUUSCPlasmidspAS8/7p1J6021 with a 1.264-bp Ndel-EcoRI fragment containing acbC inthe corresponding sitesOrsmit used for the construction of 5008 genomic library; pJ1012626pHZ2229pBlueScript II SK(+)p1Z2236Bla acZ offInsertion of a L33-kb Xbal-EcoRI fragment from ofTof TThis studypHZ2236p1Z2236Insertion of a L33-kb Xbal-EcoRI fragment from pJTU690 insandwiched between the two 2.1-kb genomic DNA fragmentsba lacZ12pJTU504pJTU514p1TU504Insertion of a 1.33-kb Xbal-EcoRI fragment from pJTU690 inbalk acZThis studypJTU516pJTU516Insertion of a 1.33-kb Xbal-EcoRI fragment from pJTU690 inbalk acZThis studypJTU504p1TU504P1TU504This studypJTU505balk acZoff transpent from pJTU515This studypJTU506Part of the 6-kb sequenced BamHI fragment from pJTU510This studypJTU690Part of the 6-kb sequenced BamHI fragment (Fig. 2)$	JXH-1	As above, but replacing a 563-bp DNA fragment internal to <i>valA</i>	This work (Fig. 5)		
E. coli strains DT10B $F^- mcrA \Delta (mrr-hsdRMS-mcrBC) 680dlacZ\DeltaM15 \Delta LacX74 deoRrecA1 endA1 ara3139 D(ara, lea)1697 galU galK \lambda^-rpsL.nupGGIBCO-BRLET12567(pUZ8002)LE392aum den hsdS/pUZ8002orom/T hsdS/p (r_e^- m_e^-) gal d em(DE3) pLysS (Cm')recA1 endA1 grA96 thi-1 hsdR17 supE44 relA1 lac31BL21Gold(DE3)/pLysSXL-1-BlueFrom T hsdS/p (r_e^- m_e^-) gal d em(DE3) pLysS (Cm')recA1 endA1 grA96 thi-1 hsdR17 supE44 relA1 lacStratagenePellicularia sasakiiFungal indicator strain sensitive to validamycin ASUUSCPlasmidspAS877p116021 with a 1.264-bp Ndel-EcoRI fragment containing acbC inthe corresponding sitesStratagenePHZ1358Cosmid used for the construction of 5008 genomic library: pU101derivative; isr Lat- sti+ oritof motion derivative; isr Cat- sti+ oritandwiched between the two 2.1-kb genomic DAA fragmentsandwiched between the two 2.1-kb genomic DAA fragmentspHZ2354This studyThis studyThis studyInsertion in BamH1 site of pHZ2234 of an aac(3)HV in EcoRI sitepHZ2354This studyThis studytragment (Fig. 2) from cosmid 3G8to p17U514This studyThis studythat al.23-kb NglH fragment from p17U696 into p18U504This studyThis studypJTU514p17U504Hold cervative with the insertion of aac(3)HV in EcoRI sitep17U516This studythe contains a linked 1.33-kb (left armp-1.4-kb aac(3)H2-2.1-kb (right arm) for val/ inactivation, in BamH1 site of p17U515This studythis studythe 1.33-kb Nbal-EcoRI fragment from p17U506 intothe studythe 1.33-kb Nbal-EcoRI fragment inserted into p101056 intothe 1.33-kb Nbal-EcoRI fragment inserted into p110456 intothe studythe 1.33-kb Nbal-EcoRI fragme$	S. lividans 66 ZX1	rec-46 str-6 pro-2	30		
DH10B $F^-mcrA \Delta(mr)-hadRMS-mcrBC) \&ValueZAMIS MacX74 deoRGIBCO-BRLET12567(pUZ8002)dam dom hadS/pUZ800221LE392supE44 supE58 hadR514, used for infection with in vitro-packaged3BL21Gold(DE3)/pLysSF^- ompT hsdS_n (r_n^- r_n^-) gal dem(DE3) pLysS (Cm-)18StratageneFreeAI endA1 gyrA90 thi-1 hadR17 supE44 relA1 lacStratagenePellicularia sasakiiFungal indicator strain sensitive to validamycin ASUUSCPlasmidspJE0021 with a 1,264-bp NdeI-EcoRI fragment containing acbC inthe corresponding sitesStratagenepBlueScript II SK(+)bla lacZ oriflStratagenepHZ1258Cosmid used for the construction of 5008 genomic library; pJ101derivative; trs Ltz sit+ orif-StratagenepHZ2220pDlueScript II SK(+)bla lacZ oriflStratagenepHZ234Construct after religation of BamH-digested 3G8This studypHZ235bla lacZInsertion of a 1.33-kb Xba1-EcoRI fragment from pTU090 insandwiched between the two 2.1-kb genomic DNA fragments12pJU295bla lacZInsertion of a 1.33-kb Xba1-EcoRI fragment from pTU090 inpBlueScript II SK(+)This studypJTU516Insertion of a 1.33-kb Xba1-EcoRI fragment from pTU515,the cast Aba1-EcoRI fragment from pTU515,the cast Aba1-Eco$	E. coli strains				
recA1 endA1 araA139 D(an, [ei)1697 galU galK λ^- rpsL nupGLE392and cm hstNpUZ800221LE392supE44 supF58 hsdR514, used for infection with in vitro-packaged cosmids3BL21Gold(DE3)/pLysSF ⁻ ompT hstNg ₀ (n ₁ m ₀) gal dcm(DE3) pLysS (Cm')18StratageneStratageneStratagenePellicularia sasakiiFungal indicator strain sensitive to validamycin ASUUSCPlasmidspL36021 with a 1.264-bp Nde1-EcoRI fragment containing acbC in the corresponding sites25plBueScript II SK(+)bla lac2 orifStratagenepHZ2229pBlueScript II SK(+)bla lac2 orifStratagenepHZ2234Cosmid used for the construction of 5008 genomic library; pJ1001 tragment (Fig. 2) from cosmid SG8This studypHZ2236Insertion in BamH1 site of pHZ2234 of an aca(3)/V geneThis studypHZ2236Insertion of a 1.33-kb Xba1-EcoRI fragment from pJTU690 in pBlueScript II SK(+)12pJTU504Insertion of a 1.33-kb Xba1-EcoRI fragment from pJTU690 in pBlueScript II SK(+)13pJTU504Insertion of a 1.33-kb Xba1-EcoRI fragment from pJTU690 in pBlueScript II SK(+)12pJTU516Insertion of a 1.33-kb Xba1-EcoRI fragment from pJTU690 in the studyThis studypJTU504PJTU504Insertion of a 1.33-kb Xba1-EcoRI fragment from pJTU690 in the studyThis studypJTU504PJTU504Insertion of a 4.33-kb (left arm)-1.4-kb aca(3)U-2.1- the studyNipJTU504Part of the 6-kb sequenced BamHI fragment inform pJTU690 in the 1.3-kb Xba1-EcoRI fragment ins	DH10B	F^- mcrA Δ (mrr-hsdRMS-mcrBC) ϕ 80dlacZ Δ M15 Δ lacX74 deoR	GIBCO-BRL		
ET12567(pUZ8002)dam dem hal3/pUZ8002Construction21LE392supF38 hal758 hal754, used for infection with in vitro-packaged cosmids3BL21Gold(DE3)/pLysS F^- ompT hal3 $_R(r_B^- m_R^-)$ gal dcm(DE3) pLysS (Cm')18StratageneFullearecl endAl grA96 thi-1 hal3R17 supE44 relAl lacStratagenePellicularia sasakiiFungal indicator strain sensitive to validamycin ASUUSCPlasmids pAS877p116021 with a 1.264-bp Ndel-EcoRI fragment containing acbC in the corresponding sites25pBlueScript II SK(+)bla lacZ orif1StratagenepHZ2229pBlueScript II SK(+) carrying a ca. 6-kb sequenced BamHI fragment (Fig. 2) from comid 3G8This studypHZ2236Insertion in BamH site of pHZ2234 of an acc(3)IV geneThis studypHZ2236Insertion of a 1.33-kb Xba1-EcoRI fragment from pJTU690 in sandwiched between the two 2.1-kb genomic DNA fragments12pJTU504p3.34b Xba1-EcoRI fragment from pJTU690 in the studyThis studypJTU514pJTU54pJTU544 bequenced BamHI fragment from pJTU690 in the cortaine with the insertion of aac(3)IV in EcoRI site the studyThis studypJTU516Insertion of a 1.33-kb Xba1-EcoRI fragment from pJTU596 into the cart with with the insertion of aac(3)IV in EcoRI site the cart of the 5-kb sequenced BamHI fragment from pJTU590 into the studyThis studypJTU516Insertion of a 4.23-kb BgII fragment from pJTU590 into the 1.33-kb Xba1-EcoRI fragment inserted into pBlueScript II SK(+)This studypJTU696Part of the 6-kb sequenced BamHI fragment (Fig. 2) including the 1.33-k		recA1 endA1 ara Δ 139 D(ara, leu)1697 galU galK λ^- rpsL nupG			
LE392 $supF38$ hsdR514, used for infection with in vitro-packaged cosmids3BL21Gold(DE3)pLysSF ⁻ ompT hsdS _B (r _B ⁻ m _B ⁻) gal dcm(DE3) pLysS (Cm')18XL-1-BlueF- ompT hsdS _B (r _B ⁻ m _B ⁻) gal dcm(DE3) pLysS (Cm')18Pellicularia sasakiiFungal indicator strain sensitive to validamycin ASJUSCPlasmidspJ5021 with a 1.264-bp Nde1-EcoRI fragment containing acbC in the corresponding sites25pBlueScript II SK(+)bla lacZ orflStratagenepHZ1358Cosmid used for the construction of 5008 genomic library; pJ1101 derivative; tsr Lz ⁻ sti ⁻ orTStratagenepHZ2229pBlueScript II SK(+) (rg, rung) a ca, chesh sequenced BamHI fragment (Fig. 2) from cosmid 3C8This studypHZ2234Construct after religation of BamHI-digested 3G8This studypJ12925bla lacZ12pTU504Insertion in BamHI site of pHZ2234 of an aac(3)IV gene sandwiched between the two 2.1-kb genomic DNA fragments12pTU514pTU504 derivative with the insertion of aac(3)IV and construction of the studyThis studypJTU515Insertion of a 1.33-kb XbaI-EcoRI fragment from pJTU690 in bla lacZThis studypTU516Insertion of a 4.23-kb BgIII fragment from pJTU696 into the che sequenced BamHI fragment (Fig. 2) including the che sequenced BamHI fragment (Fig. 2) including the che sequenced BamHI fragment (Fig. 2) including the 1.3-kb VauI-EcoRI fragment from pJTU696 into the studyThis studypTU516Insertion of a 4.23-kb BgIII fragment from pJTU696 into the che sequenced BamHI fragment (Fig. 2) including the 1.3-kb VauI-EcoRI fragm	ET12567(pUZ8002)	dam dcm hsdS/pUZ8002	21		
BL2IGold(DE3)/pLysS XL-1-Blue $F^- ompT hsdS_h (r_h^- m_h^-) gal dom(DE3) pLysS (Cm^4)$ 18 StratagenePellicularia sasakiiFungal indicator strain sensitive to validamycin ASJUSCPlasmids pAS8/7pIJ6021 with a 1.264-bp Ndel-EcoRI fragment containing acbC in the corresponding sites25 StratagenePBlueScript II SK(+)bla lacZ orif1SK(+) of the corresponding sitesStratagenePJZ2229pBlueScript II SK(+) of the accd or the construction of 5008 genomic library; pJJ101 derivative; tsr Ltz sti ⁻ oriT orig a ca. 6-kb sequenced BamHI fragment (Fig. 2) from cosmid 3G8This studypJZ2234Construct after religation of BamH-digested 3G8This studypJI2925bla lacZ13 KU+0 construct from of BamH-digested 3G8This studypJI2925bla lacZDia lacZ12pTU504Insertion of a 1.3-3-kb Xbal-EcoRI fragment from pJTU690 in pJTU514This studypJTU516Insertion of 1.3-kb Pull-HindIII fragment from pJTU690 in beart of the 6-kb sequenced BamHI fragment from pJTU690 in the studyThis studypJTU516Insertion of a 4.2-3-kb BgII fragment from pJTU690 in beart of the 6-kb sequenced BamHI fragment from pJTU690 in the studyThis studypJTU516Part of the 6-kb sequenced BamHI fragment from pJTU690 in to 1.3-kb Vbal-EcoRI fragment from pJTU696 into the studyThis studypJTU516Part of the 6-kb sequenced BamHI fragment from pJTU696 into the his studyThis studypJTU690Part of the 6-kb sequenced BamHI fragment (Fig. 2) including the 1.3-kb Vbal-EcoRI fragment from pJTU696 into this studyTh	LE392	supE44 supF58 hsdR514, used for infection with in vitro-packaged cosmids	3		
XL-1-BluerecAI and AI grA96 thi-1 hadR17 supE44 relAI lacStratagenePellicularia sasakiiFungal indicator strain sensitive to validamycin ASJUSCPlasmids pAS8/7plf021 with a 1.264-bp NdeI-EcoRI fragment containing $acbC$ in the corresponding sites25pBlueScript II SK(+)bla lacZ orf1StratagenepHZ2229pBlueScript II SK(+) carrying a ca. 6-kb sequenced BamHI fragment (Fig. 2) from cosmid 3G8This study fragment (Fig. 2) from cosmid 3G8pHZ2234Construct after religation of BamHI-digested 3G8This study pHZ2236pHZ2255bla lacZ12pJTU504Insertion of a 1.33-kb Xba1-EcoRI fragment from pJTU690 in BueScript II SK(+)This study pBlueScript II SK(+)pJTU514pJTU504Insertion of a 1.33-kb Xba1-EcoRI fragment from pJTU690 in BueScript II SK(+)pJTU515Insertion of a 4.23-kb Bull fragment from pJTU690 in EcoRV-HindIII sites of pJTU514pJTU516Insertion of a 4.23-kb Bull fragment from pJTU55, which contains a linked 1.33-kb (left arm) 1.4-kb aac(3)U/2.1-t kb (right arm) for val/ inactivation, in BamHI site of pHZ1358pJTU690Part of the 6-kb sequenced BamHI fragment (Fig. 2) including the 1.3-kb Yba1-EcoRI fragment inserted into pBlueScript II SK(+)This study which contains a linked 1.33-kb (left arm) 1.4-kb aac(3)U/2.1-t kb (right arm) for val/ inactivation, in BamHI site of pHZ1358pJTU690Part of the 6-kb sequenced BamHI fragment (Fig. 2) including the 1.3-kb Yba1-EcoRI fragment inserted into pBlueScript II SK(+)This study the 1.3-kb PvuII-HindIII fragment (Fig. 2) including the 1.3-kb PvuII-HindIII fragment (Fig. 2) including <br< td=""><td>BL21Gold(DE3)/pLysS</td><td>F^- ompT hsdS_p ($r_p^- m_p^-$) gal dcm(DE3) pLysS (Cm^r)</td><td>18</td></br<>	BL21Gold(DE3)/pLysS	F^- ompT hsdS _p ($r_p^- m_p^-$) gal dcm(DE3) pLysS (Cm ^r)	18		
Pellicularia sasakiiFungal indicator strain sensitive to validamycin ASJUSCPlasmids pAS87pJI6021 with a 1,264-bp NdeI-EcoRI fragment containing $acbC$ in the corresponding sites25pBlueScript II SK(+)bla lacZ orf1Stratagene 26pHZ2229pBlueScript II SK(+) carrying a ca. 6-kb sequenced BamHI fragment (Fig. 2) from cosmid 3G8This studypHZ2234Construct fare religation of BamHI-digested 3G8This studypHZ2235bla lacZ orf1Is remember of bal lacZ orf112pHZ2236Construct fare religation of BamHI-digested 3G8This studypHZ2236Insertion of a 1.33-kb Xba1-EcoRI fragment from pJTU690 in pJTU514This studypJTU504Insertion of a 1.33-kb Xba1-EcoRI fragment from pJTU690 in Full steet of pJTU515This studypJTU516Insertion of a 4.23-kb b gall fragment from pJTU690 in Full steet of pJTU516This studypJTU516Insertion of a 4.23-kb b gall fragment from pJTU690 in Full steet of pJTU515This studypJTU516Insertion of a 4.23-kb b gall fragment from pJTU690 in Full steet of pJTU515This studypJTU690Part of the 6-kb sequenced BamHI fragment (Fig. 2) including the 1.33-kb Vba1-EcoRI fragment from pJTU696 into EcoRV-HindIII steet of pJTU515This studypJTU690Part of the 6-kb sequenced BamHI fragment (Fig. 2) including the 1.33-kb Vba1-EcoRI fragment from pJTU690This studypJTU696Part of the 6-kb sequenced BamHI fragment (Fig. 2) including the 1.3-kb Vvull-HindIII fragment (Fig. 2) including the 1.3-kb Vvull-HindIII fragment (Fig. 2) including the 1.3-kb Vvull-Hin	XL-1-Blue	recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac	Stratagene		
Pedlicularia sasakiiFungal indicator strain sensitive to validamycin ASJUSCPlasmids pAS8/7pJJ6021 with a 1,264-bp NdeI-EcoRI fragment containing <i>acbC</i> in the corresponding sites25pBlueScript II SK(+) <i>bla lacZ orif1</i> Stratagene orifpHZ2229pBlueScript II SK(+) carrying a <i>ca.</i> 6-kb sequenced BamHI fragment (Fig. 2) from cosmid 3G8This study fragment SG8pHZ2234Construct after religation of BamHI-digested 3G8This studypHZ2236Insertion of a 1.33-kb XbaI-EcoRI fragment from pJTU690 in pHZ223612pJTU504Insertion of a 1.33-kb XbaI-EcoRI fragment from pJTU690 in pJTU51412pJTU504Insertion of a 1.33-kb XbaI-EcoRI fragment from pJTU690 in pJTU514This study pBlueScript II SK(+)pJTU504Insertion of a 1.33-kb XbaI-EcoRI fragment from pJTU690 in pJTU514This study pBlueScript II SK(+)pJTU504Insertion of a 1.33-kb XbaI-EcoRI fragment from pJTU690 in pJTU514This study pBlueScript II SK(+)pJTU504Insertion of a 1.33-kb XbaI-EcoRI fragment from pJTU690 in pJTU516This study This study recoRV-HindIII stes of pJTU514pJTU506Part of the 6-kb sequenced BamHI fragment (Fig. 2) including the 1.33-kb XbaI-EcoRI fragment inserted into pBlueScript II SK(+)This study rhis study which contains a linked 1.33-kb (fig agment inserted into pBlueScript II SK(+)pJTU690Part of the 6-kb sequenced BamHI fragment (Fig. 2) including the 1.33-kb XbaI-EcoRI fragment inserted into pBlueScript II SK(+)This study rhis study rhis study the 1.35-kb YvaII-HindIII fragment (Fig. 2) including the 1.33-kb			~8		
Plasmids pAS8/7pIJ6021 with a 1,264-bp NdeI-EcoRI fragment containing $acbC$ in the corresponding sites25pBlueScript II SK(+) pHZ1358 $bla lacZ orif1$ Stratagene Cosmid used for the construction of 5008 genomic library; pIJ101 derivative; $tr. La^-$ sit* ori7Stratagene 26pHZ2229pBlueScript II SK(+) carrying a ca. 6-kb sequenced BamHI fragment (Fig. 2) from cosmid 3G8 pHZ2234This study fragment (Fig. 2) from cosmid 3G8 construct after religation of BamHI-digested 3G8 sandwiched between the two 2.1-kb genomic DNA fragments12pIJ2925bla lacZ vandwiched between the two 2.1-kb genomic DNA fragments12pTU504Insertion of a 1.33-kb XbaI-EcoRI fragment from pJTU690 in pJTU514This study This study pITU514pJTU516Insertion of 1.5-kb PvuII-HindIII fragment from pJTU696 into EcoRV-HindIII sites of pJTU514This study This study EcoRV-HindIII sites of pJTU514pJTU516Insertion of a 4.23-kb BgII fragment from pJTU696 into teoRV-HindIII sited 1.33-kb (left arm)-14-kb act/31V-2.1- kb (right arm) for val4 inactivation, in BamHI site of pHZ1358This studypJTU690Part of the 6-kb sequenced BamHI fragment (Fig. 2) including the 1.3-kb PvuII-HindIII fragment inserted into pBlueScript II SK(+)This studypJTU690Part of the 6-kb sequenced BamHI fragment (Fig. 2) including the 1.3-kb PvuII-HindIII fragment inserted into pBlueScript II SK(+)This studypJTU696Part of the 6-kb sequenced BamHI fragment inserted into pBlueScript II	Pellicularia sasakii	Fungal indicator strain sensitive to validamycin A	SJUSC		
pAS8/7pJ6021 with a 1,264-bp Ndel-EcoRI fragment containing $acbC$ in the corresponding sites25pBlueScript II SK(+)bla lacZ orif1Stratagene 26pHZ2239pBlueScript II SK(+) carrying a $ca. 6$ -kb sequenced BamHIThis study rfagment (Fig. 2) from cosmid 3G8This studypHZ2234Construct after religation of BamHI-digested 3G8This studypHZ2236Insertion in BamHI site of pHZ2234 of an $aac(3)IV$ geneThis studypJU2925bla lacZIlaI2pTU504Insertion of a 1.33-kb XbaI-EcoRI fragment from pJTU690 in pBlueScript II SK(+)This studypTU514pJTU504 derivative with the insertion of $aac(3)IV$ in EcoRI siteThis studypTU516Insertion of a 4.23-kb BgII fragment from pJTU696 into tecoRV-HindIII is of pJTU514This studypJTU516Insertion of a 4.23-kb BgII fragment from pJTU696 into tecoRV-HindIII is of pJTU514This studypJTU516Insertion of a 4.23-kb BgII fragment from pJTU515, which contains a linked 1.33-kb (left arm)-1.4kb $aac(3)IV-2.1-$ kb (right arm) for vaA inactivation, in BamHI site of pHZ1558This studypJTU690Part of the 6-kb sequenced BamHI fragment (Fig. 2) including the 1.3-kb ValI-EcoRI fragment inserted into pBlueScript II SK(+)This studypKMW5pUC18 derivative carrying the srD and srE genes of the streptomycin pathway24pKMW5bla la cZ28Phage $\PhiC31$ Wild type; c^+ attP ⁺ int ⁺ 31	Plasmids				
pBlueScript II SK(+)bla lacZ orif1StratagenepHZ1358Cosmid used for the construction of 5008 genomic library; pIJ10126pHZ2229pBlueScript II SK(+) carrying a ca. 6-kb sequenced BamHIThis studypHZ2234Construct after religation of BamHI-diggestd 3G8This studypHZ2236Insertion in BamHI site of pHZ2234 of an acc(3)IV geneThis studypJT0504Insertion of a 1.33-kb XbaI-EcoRI fragment from pJTU690 inThis studypJTU514pJTU504Insertion of 1.54b PvuII-HindIII fragment from pJTU690 inThis studypJT0515Insertion of a 1.33-kb XbaI-EcoRI fragment from pJTU696 intoThis studypJT0516Insertion of a 4.33-kb Bull fragment from pJTU696 intoThis studypJT0516Insertion of a 4.23-kb BgIII fragment from pJTU696 intoThis studypJT056Viright arm) for va/A inactivation, in BamHI site of pHZ1358This studypJTU690Part of the 6-kb sequenced BamHI fragment (Fig. 2) includingThis studythe 1.33-kb VbaI-EcoRI fragment inserted into pBlueScript IISK(+)This studypJTU696Part of the 6-kb sequenced BamHI fragment (Fig. 2) includingThis studythe 1.33-kb VbaI-EcoRI fragment inserted into pBlueScript IISK(+)This studypKWV5pUCI8 derivative carrying the strD and strE genes of the24streptomycin pathwaygK(+)ZZpKWV5bla lacZZZpKWV5bla lacZZpKWV5bla lacZZpKWV5bla lacZZpKWV5bla	pAS8/7	pIJ6021 with a 1,264-bp NdeI-EcoRI fragment containing acbC in	25		
pBlueScript II SK(+)bla lacZ orif1StratagenepHZ1358Cosmid used for the construction of 5008 genomic library; pJ10126pHZ2229pBlueScript II SK(+) carrying a ca. 6-kb sequenced BamHIThis studyrfagment (Fig. 2) from cosmid 3G8This studypHZ2234Construct after religation of BamHI-digested 3G8This studypHZ2236Insertion in BamHI site of pHZ2234 of an aac(3)IV geneThis studypJTU504Insertion of a 1.33-kb Xbal-EcoRI fragment from pJTU690 inThis studypJTU514pJTU504 derivative with the insertion of aac(3)IV in EcoRI siteThis studypJTU515Insertion of a 4.23-kb BgIII fragment from pJTU696 intoThis studypJTU516Insertion of a 4.23-kb BgIII fragment from pJTU696 intoThis studypJTU516Insertion of a 4.23-kb BgIII fragment from pJTU515, which contains a linked 1.33-kb (felt arm)-1.4-kb aac(3)IV-2.1- kb (right arm) for ald inactivation, in BamHI site of pHZ1358This studypJTU690Part of the 6-kb sequenced BamHI fragment (Fig. 2) including the 1.3-kb Vall-EcoRI fragment inserted into pBlueScript II SK(+)This studypJTU696Part of the 6-kb sequenced BamHI fragment (Fig. 2) including the 1.5-kb Pvull-HindIII fragment inserted into pBlueScript II SK(+)This studypKWW5pUC18derivative carrying the strD and strE genes of the streptomycin pathway24pRSET-Bbla rep ^{FUC} , T7 promoter bla lacZInvitrogen 28Phage $\phiC31$ Wild type; c^+ attP* int*31	1	the corresponding sites			
pHZ1358Cosmid used for the construction of 5008 genomic library; pJ10126pHZ2229pBlueScript II SK(+) carrying a ca. 6-kb sequenced BamHIThis studypHZ2234Construct after religation of BamHI-digested 3G8This studypHZ2236Insertion in BamHI site of pHZ2234 of an aac(3)IV geneThis studypJI2925bla lacZ12pJTU504Insertion of a 1.33-kb Xba1-EcoRI fragment from pJTU690 inThis studypJTU514pJTU504 derivative with the insertion of aac(3)IV in EcoRI siteThis studypJTU515Insertion of 1.5-kb PvuII-HindIII fragment from pJTU696 intoThis studypJTU516Insertion of 1.5-kb PvuII-HindIII fragment from pJTU696 intoThis studypJTU516Insertion of a 1.33-kb Xba1-EcoRI fragment from pJTU696 intoThis studypJTU516Insertion of 1.5-kb PvuII-HindIII fragment from pJTU696 intoThis studypJTU516Insertion of a 4.23-kb RgII fragment from pJTU515,This studypJTU690Part of the 6-kb sequenced BamHI fragment (Fig. 2) includingThis studythe 1.33-kb Xba1-EcoRI fragment inserted into pBlueScript IISK(+)This studypJTU696Part of the 6-kb sequenced BamHI fragment (Fig. 2) includingThis studythe 1.5-kb PvuII-HindIII fragment inserted into pBlueScript IISK(+)Z8pKMW5pUC18 derivative carrying the strD and strE genes of the streptomycin pathwayZ4pKMW5bla lacZZ8	pBlueScript II SK(+)	bla lacZ orif1	Stratagene		
pHZ2229pBlueScript II SK(+) carrying a ca. 6-kb sequenced BamHIThis studypHZ2234Construct after religation of BamHI-digested 3G8This studypHZ2236Insertion in BamHI site of pHZ2234 of an $aac(3)IV$ geneThis studypJI2925 $bla lacZ$ 12pJTU504Insertion of a 1.33-kb XbaI-EcoRI fragment from pJTU690 in pBlueScript II SK(+)This studypJTU514pJTU504 derivative with the insertion of $aac(3)IV$ in EcoRI site EcoRV-HindIII sites of pJTU515This studypJTU516Insertion of a 4.23-kb BglII fragment from pJTU696 into EcoRV-HindIII sites of pJTU515, which contains a linked 1.33-kb (left arm)-1.4-kb $aac(3)IV-2.1-$ kb (right arm) for $valA$ inactivation, in BamHI site of pHZ1358This studypJTU690Part of the 6-kb sequenced BamHI fragment (Fig. 2) including the 1.33-kb XbaI-EcoRI fragment inserted into pBlueScript II SK(+)This studypJTU696Part of the 6-kb sequenced BamHI fragment (Fig. 2) including the 1.5-kb PvIII-HindIII fragment (Fig. 2) including the 1.5-kb PvIII-HindIII fragment inserted into pBlueScript II SK(+)This studypKWW5pUC18 derivative carrying the $strD$ and $strE$ genes of the streptomycin pathway24pRSET-B pUC18 $bla lacZ$ 28Phage $\phiC31$ Wild type; c^+ $attP^+$ int^+ 31	pHZ1358	Cosmid used for the construction of 5008 genomic library; pIJ101 derivative: $tsr Ltz^- sti^+ oriT$	26		
pHZ2234 pHZ2236Construct after religation of BamHI-digested 3G8 Insertion in BamHI site of pHZ2234 of an $aac(3)IV$ gene sandwiched between the two 2.1-kb genomic DNA fragmentsThis studypJI2925 $bla lacZ$ 12pJTU504Insertion of a 1.33-kb XbaI-EcoRI fragment from pJTU690 in pBlueScript II SK(+)12pJTU514pJTU504 derivative with the insertion of $aac(3)IV$ in EcoRI site tecoRV-HindIII sites of pJTU515This studypJTU516Insertion of 1.5-kb PvuII-HindIII fragment from pJTU696 into EcoRV-HindIII sites of pJTU514This studypJTU516Insertion of a 4.23-kb BgIII fragment from pJTU515, which contains a linked 1.33-kb (left arm)-1.4-kb $aac(3)IV-2.1$ - kb (right arm) for $vaIA$ inactivation, in BamHI site of pHZ1358This studypJTU690Part of the 6-kb sequenced BamHI fragment (Fig. 2) including the 1.33-kb XbaI-EcoRI fragment inserted into pBlueScript II SK(+)This studypJTU696Part of the 6-kb sequenced BamHI fragment (Fig. 2) including the 1.5-kb PvuII-HindIII fragment inserted into pBlueScript II SK(+)This studypKMW5pUC18 derivative carrying the $strD$ and $strE$ genes of the streptomycin pathway24pRSET-B pUC18 $bla rep^{pUC}$, 77 promoter $bla lacZZ$	pHZ2229	pBlueScript II SK(+) carrying a <i>ca</i> . 6-kb sequenced BamHI fragment (Fig. 2) from cosmid 3G8	This study		
pHZ2236Insertion in BamHI site of pHZ2234 of an $aac(3)IV$ geneThis studypJJ2925 $bla lacZ$ 12pJTU504Insertion of a 1.33-kb XbaI-EcoRI fragment from pJTU690 in pBlueScript II SK(+)12pJTU514pJTU504 derivative with the insertion of $aac(3)IV$ in EcoRI siteThis studypJTU515Insertion of 1.5-kb PvuII-HindIII fragment from pJTU696 into EcoRV-HindIII sites of pJTU515This studypJTU516Insertion of a 4.23-kb BglII fragment from pJTU696 into EcoRV-HindIII sites of pJTU515, to right arm) for valA inactivation, in BamHI site of pHZ1358This studypJTU690Part of the 6-kb sequenced BamHI fragment (Fig. 2) including the 1.33-kb XbaI-EcoRI fragment inserted into pBlueScript II SK(+)This studypJTU696Part of the 6-kb sequenced BamHI fragment (Fig. 2) including the 1.5-kb PvuII-HindIII fragment inserted into pBlueScript II SK(+)This studypKMW5pUC18 derivative carrying the strD and strE genes of the streptomycin pathway24pRSET-B pUC18bla acZ 28Phage $\phiC31$ Wild type; c^+ att P^+ int^+31	pHZ2234	Construct after religation of BamHI-digested 3G8	This study		
sandwiched between the two 2.1-kb genomic DNA fragments12pJI2925bla lacZ12pJTU504Insertion of a 1.33-kb Xba1-EcoRI fragment from pJTU690 in pBlueScript II SK(+)This studypJTU514pJTU504 derivative with the insertion of $aac(3)IV$ in EcoRI siteThis studypJTU515Insertion of 1.5-kb Pvul1-HindIII fragment from pJTU696 into EcoRV-HindIII sites of pJTU514This studypJTU516Insertion of a 4.23-kb BgII fragment from pJTU515, which contains a linked 1.33-kb (left arm)-1.4-kb $aac(3)IV-2.1$ - kb (right arm) for valA inactivation, in BamHI site of pHZ1358This studypJTU690Part of the 6-kb sequenced BamHI fragment (Fig. 2) including the 1.33-kb XbaI-EcoRI fragment inserted into pBlueScript II SK(+)This studypJTU696Part of the 6-kb sequenced BamHI fragment (Fig. 2) including the 1.5-kb Pvul1-HindIII fragment inserted into pBlueScript II SK(+)This studypKMW5pUC18 derivative carrying the strD and strE genes of the streptomycin pathway24pRSET-B pUC18bla lacZ28Phage $\phiC31$ Wild type; c^+ att P^+ int $^+$ 31	pHZ2236	Insertion in BamHI site of pHZ2234 of an <i>aac(3)IV</i> gene	This study		
pIJ2925 $bla lacZ$ 12pJTU504Insertion of a 1.33-kb XbaI-EcoRI fragment from pJTU690 in pBlueScript II SK(+)This study pJTU504 derivative with the insertion of $aac(3)IV$ in EcoRI siteThis studypJTU514pJTU504 derivative with the insertion of $aac(3)IV$ in EcoRI siteThis studypJTU515Insertion of 1.5-kb PvuII-HindIII fragment from pJTU696 intoThis studypJTU516Insertion of a 4.23-kb BgII fragment from pJTU515, which contains a linked 1.33-kb Ueft arm)-1.4-kb $aac(3)IV-2.1$ - kb (right arm) for $valA$ inactivation, in BamHI site of pHZ1358This studypJTU690Part of the 6-kb sequenced BamHI fragment (Fig. 2) including the 1.33-kb XbaI-EcoRI fragment inserted into pBlueScript II SK(+)This study the 1.33-kb XbaI-EcoRI fragment inserted into pBlueScript II SK(+)pJTU696Part of the 6-kb sequenced BamHI fragment (Fig. 2) including the 1.5-kb PvuII-HindIII fragment inserted into pBlueScript II SK(+)This studypKMW5pUC18 derivative carrying the <i>strD</i> and <i>strE</i> genes of the streptomycin pathway24pRSET-B pUC18 <i>bla acZ</i> 28Phage $\phiC31$ Wild type; c^+ att P^+ int^+31	1	sandwiched between the two 2.1-kb genomic DNA fragments	5		
pJTU504Insertion of a 1.33-kb XbaI-EcoRI fragment from pJTU690 in pBlueScript II SK(+)This studypJTU514pJTU504 derivative with the insertion of $aac(3)IV$ in EcoRI siteThis studypJTU515Insertion of 1.5-kb PvIII-HindIII fragment from pJTU696 into EcoRV-HindIII sites of pJTU514This studypJTU516Insertion of a 4.23-kb BgIII fragment from pJTU515, kb (right arm) for $valA$ inactivation, in BamHI site of pHZ1358This studypJTU690Part of the 6-kb sequenced BamHI fragment (Fig. 2) including the 1.33-kb XbaI-EcoRI fragment inserted into pBlueScript II SK(+)This studypJTU696Part of the 6-kb sequenced BamHI fragment (Fig. 2) including the 1.5-kb PVIII-HindIII fragment inserted into pBlueScript II SK(+)This studypKMW5pUC18 derivative carrying the $strD$ and $strE$ genes of the streptomycin pathway24pRSET-B pUC18bla rep^{pUC} , 77 promoter bla $lacZ$ Invitrogen 28Phage $\phiC31$ Wild type; c^+ $attP^+$ int^+31	pIJ2925	bla lacZ	12		
pJTU514pJTU504 derivative with the insertion of $aac(3)IV$ in EcoRI siteThis studypJTU515Insertion of 1.5-kb PvuII-HindIII fragment from pJTU696 intoThis studypJTU516Insertion of a 4.23-kb BgII fragment from pJTU515, which contains a linked 1.33-kb (left arm)-1.4-kb $aac(3)IV$ -2.1- kb (right arm) for valA inactivation, in BamHI site of pHZ1358This studypJTU690Part of the 6-kb sequenced BamHI fragment (Fig. 2) including SK(+)This studyThis studypJTU696Part of the 6-kb sequenced BamHI fragment (Fig. 2) including the 1.5-kb PvuII-HindIII fragment inserted into pBlueScript II SK(+)This studypKMW5pUC18 derivative carrying the strD and strE genes of the streptomycin pathway24pRSET-B pUC18bla rep^{pUC} , T7 promoter bla $lacZ$ Invitrogen 28Phage $\phiC31$ Wild type; c^+ attP ⁺ int ⁺ 31	pJTU504	Insertion of a 1.33-kb XbaI-EcoRI fragment from pJTU690 in pBlueScript II SK(+)	This study		
pJTU515Insertion of 1.5-kb PvuII-HindIII fragment from pJTU696 into EcoRV-HindIII sites of pJTU514This studypJTU516Insertion of a 4.23-kb BgIII fragment from pJTU515, which contains a linked 1.33-kb (left arm)-1.4-kb $aac(3)IV-2.1$ - kb (right arm) for valA inactivation, in BamHI site of pHZ1358This studypJTU690Part of the 6-kb sequenced BamHI fragment (Fig. 2) including 	pJTU514	pJTU504 derivative with the insertion of $aac(3)IV$ in EcoRI site	This study		
PJTU516EcoRV-HindIII sites of pJTU514PJTU514pJTU516Insertion of a 4.23-kb BgIII fragment from pJTU515, which contains a linked 1.33-kb (left arm)-1.4-kb $aac(3)IV$ -2.1- kb (right arm) for $valA$ inactivation, in BamHI site of pHZ1358This studypJTU690Part of the 6-kb sequenced BamHI fragment (Fig. 2) including the 1.33-kb XbaI-EcoRI fragment inserted into pBlueScript II SK(+)This studypJTU696Part of the 6-kb sequenced BamHI fragment (Fig. 2) including the 1.5-kb PvuII-HindIII fragment inserted into pBlueScript II SK(+)This studypKMW5pUC18 derivative carrying the $strD$ and $strE$ genes of the streptomycin pathway24pRSET-B pUC18 $bla rep^{pUC}$, T7 promoter $bla lacZ$ Invitrogen 28Phage $\phiC31$ Wild type; $c^+ attP^+ int^+$ 31	pJTU515	Insertion of 1.5-kb PvuII-HindIII fragment from pJTU696 into	This study		
pJTU516Insertion of a 4.23-kb BgIII fragment from pJTU515, which contains a linked 1.33-kb (left arm)-1.4-kb $aac(3)IV$ -2.1- kb (right arm) for $valA$ inactivation, in BamHI site of pHZ1358This studypJTU690Part of the 6-kb sequenced BamHI fragment (Fig. 2) including the 1.33-kb XbaI-EcoRI fragment inserted into pBlueScript II SK(+)This studypJTU696Part of the 6-kb sequenced BamHI fragment (Fig. 2) including the 1.5-kb PvuII-HindIII fragment inserted into pBlueScript II SK(+)This studypKMW5pUC18 derivative carrying the <i>strD</i> and <i>strE</i> genes of the streptomycin pathway bla $lacZ$ 24Phage $\phiC31$ Wild type; c^+ $attP^+$ int^+31	I · · · ·	EcoRV-HindIII sites of pJTU514			
pJTU690which contains a linked 1.33-kb (left arm)-1.4-kb $aac(3)IV$ -2.1- kb (right arm) for $valA$ inactivation, in BamHI site of pHZ1358pJTU690Part of the 6-kb sequenced BamHI fragment (Fig. 2) including the 1.33-kb XbaI-EcoRI fragment inserted into pBlueScript II SK(+)This studypJTU696Part of the 6-kb sequenced BamHI fragment (Fig. 2) including the 1.5-kb PvuII-HindIII fragment inserted into pBlueScript II SK(+)This studypKMW5pUC18 derivative carrying the $strD$ and $strE$ genes of the streptomycin pathway24pRSET-B pUC18bla rep^{pUC} , T7 promoter bla $lacZ$ Invitrogen 28Phage $\phiC31$ Wild type; $c^+ attP^+ int^+$ 31	pJTU516	Insertion of a 4.23-kb BgIII fragment from pJTU515.	This study		
kb (right arm) for valA inactivation, in BamHI site of pHZ1358pJTU690Part of the 6-kb sequenced BamHI fragment (Fig. 2) including the 1.33-kb XbaI-EcoRI fragment inserted into pBlueScript II SK(+)This studypJTU696Part of the 6-kb sequenced BamHI fragment (Fig. 2) including the 1.5-kb PvuII-HindIII fragment inserted into pBlueScript II SK(+)This studypKMW5pUC18 derivative carrying the strD and strE genes of the streptomycin pathway24pRSET-B pUC18bla rep ^{pUC} , T7 promoter bla lacZInvitrogen 28Phage $\phiC31$ Wild type; c^+ attP ⁺ int ⁺ 31	1	which contains a linked 1.33-kb (left arm)-1.4-kb <i>aac(3)IV</i> -2.1-	5		
pJTU690Part of the 6-kb sequenced BamHI fragment (Fig. 2) including the 1.33-kb XbaI-EcoRI fragment inserted into pBlueScript II SK(+)This studypJTU696Part of the 6-kb sequenced BamHI fragment (Fig. 2) including the 1.5-kb PvuII-HindIII fragment inserted into pBlueScript II SK(+)This studypKMW5pUC18 derivative carrying the <i>strD</i> and <i>strE</i> genes of the streptomycin pathway24pRSET-B pUC18 <i>bla rep</i> ^{pUC} , T7 promoter <i>bla lacZ</i> Invitrogen 28Phage $\phiC31$ Wild type; c^+ att P^+ int^+31		kb (right arm) for <i>valA</i> inactivation, in BamHI site of pHZ1358			
pJTU696 Part of the 6-kb sequenced BamHI fragment (Fig. 2) including This study the 1.5-kb PvuII-HindIII fragment inserted into pBlueScript II SK(+) pKMW5 pUC18 derivative carrying the <i>strD</i> and <i>strE</i> genes of the 24 streptomycin pathway pRSET-B bla rep^{pUC} , T7 promoter Invitrogen 28 Phage ϕ C31 Wild type; c^+ att P^+ int ⁺ 31	pJTU690	Part of the 6-kb sequenced BamHI fragment (Fig. 2) including the 1.33-kb XbaI-EcoRI fragment inserted into pBlueScript II	This study		
pJ10696Part of the 6-kb sequenced BamHI fragment (Fig. 2) includingThis studythe 1.5-kb PvuII-HindIII fragment inserted into pBlueScript II $SK(+)$ 24pKMW5pUC18 derivative carrying the <i>strD</i> and <i>strE</i> genes of the streptomycin pathway24pRSET-B pUC18bla rep ^{pUC} , T7 promoter bla lacZInvitrogen 28Phage $\phiC31$ Wild type; c^+ att P^+ int^+31		SK(+)			
pKMW5pUC18bla rep^{pUC} , T7 promoter24pRSET-B pUC18bla rep^{pUC} , T7 promoterInvitrogen 28Phage $\phi C31$ Wild type; c^+ att P^+ int $^+$ 31	pJ 1 0 696	the 1.5-kb PvuII-HindIII fragment inserted into pBlueScript II	I his study		
pRSET-B pUC18bla rep^{pUC} , T7 promoter bla $lacZ$ Invitrogen 28Phage $\phi C31$ Wild type; c^+ att P^+ int $^+$ 31	nKMW5	nUC18 derivative carrying the strD and strE genes of the	24		
pRSET-B pUC18bla rep rep Invitrogen 28Phage $\phi C31$ Wild type; c^+ att P^+ int $^+$ 31	printito	streptomycin nathway	21		
pUC18bla lacZ28Phage $\phi C31$ Wild type; c^+ att P^+ int $^+$ 31	pRSET-B	<i>bla rep^{pUC}</i> . T7 promoter	Invitrogen		
Phage $\phi C31$ Wild type; $c^+ attP^+ int^+$ 31	nUC18	bla lacZ	28		
Phage ϕ C31 Wild type; c^+ att P^+ int $^+$ 31	P C C I O		20		
$\phi \overline{C31}$ Wild type; $c^+ attP^+ int^+$ 31	Phage				
	фC31	Wild type; c^+ att P^+ int ⁺	31		

TABLE 1.	Strains,	phage,	plasmids,	and	cosmids	used	in	this	stud	y
----------	----------	--------	-----------	-----	---------	------	----	------	------	---

^{*a*} Ltz (lethal zygosis), pock formation caused by plasmid transfer; *mel*, tyrosinase gene for melanin production; *oriT*, origin of transfer of plasmid RK2; *tsr*, thiostrepton resistance gene; *aac(3)IV*, apramycin resistance gene; *sti*, origin for second-strand synthesis of the multicopy plasmid pIJ101 (6); *vph*, viomycin resistance gene; *xylE*, catechol 2,3-dioxygenase from *Pseudomonas putida*; Cm^r, chloramphenicol resistance gene.

The *valA* gene was amplified by PCR with Platinum Pfx DNA polymerase (Invitrogen) using the cosmid clone 3G8 as the template and primers ValA-F3, 5'-GAAGATCTGCATATGACCAAGCAGAGTTCCTTATCC-3' (BglII and Ndel), and ValA-R2, 5'-GGAATTCTCACACCCCCATGTCCACGGCACC G-3' (EcoRI). PCR amplification was done in a Thermocycler (Eppendorf, Mastercycler gradient) under the following conditions: 33 cycles of 90 s at 95°C, 45 s at 60°C, and 45 s at 72°C. The PCR products were digested with BglII and EcoRI, and subsequently ligated into BamHI- and EcoRI-digested pRSET-B. The constructs were transformed into *E. coli* XL-1-Blue and plated on LB agar plates containing 100 µg ml⁻¹ ampicillin.

The plasmid DNA was isolated and introduced by heat-pulse transformation

into *E. coli* BL21Gold(DE3)/pLysS (Stratagene), which was then plated onto LB agar plates containing 100 μ g ml⁻¹ ampicillin and 25 μ g ml⁻¹ chloramphenicol. The transformants were grown in 20 ml LB medium containing ampicillin and chloramphenicol at 37°C to an optical density at 600 nm of 0.6. Isopropyl- β -D-thiogalactopyranoside (IPTG) was added to a final concentration of 0.2 mM and the incubation was continued at 28°C for 24 h. The cells were harvested by centrifugation at 3,500 rpm for 15 min and stored frozen at -80°C until further use.

Preparation of cell extracts and purification of His₆**-tagged ValA.** Cells were thawed and resuspended in disruption buffer (50 mM NaH₂PO₄, 300 mM NaCl, 10 mM imidazole, pH 8.0). The suspension was sonicated three times for 25 s



FIG. 2. Overlapping cosmids covering genes for validamycin biosynthesis and gene organization of the 6-kb sequenced region. Top: BamHI restriction map of the ca. 70-kb contig for validamycin biosynthesis. The solid bar indicates the 30-kb deleted region in Fig. 3, which abolished validamycin production. Bottom: 6-kb sequenced region including the *acbC* homologue (*valA*). B: BamHI site. B': regenerated BamHI site from BamHI (vector) and MboI (insert) sites.

each and cell debris was removed by centrifugation at 10,000 rpm for 10 min. The protein solution was applied to an Ni-nitrilotriacetic acid spin column (QIA-GEN) and centrifuged at 2,000 rpm for 2 min. The column was washed with washing buffer (50 mM NaH₂PO₄, 300 mM NaCl, 20 mM imidazole, pH 8.0, and 50 mM NaH₂PO₄, 300 mM NaCl, 100 mM imidazole, pH 8.0). The His₆-tagged protein was eluted with elution buffer (50 mM NaH₂PO₄, 300 mM NaCl, 200 mM inidazole, pH 8.0) and dialyzed for 24 h against 1 liter of dialysis buffer (20 mM potassium phosphate [pH 7.4], 0.05 mM CoCl₂, 2 mM KF and 0.5 mM dithio-threitol). Protein concentration was measured by the Bradford protein microassay with bovine serum albumin as the standard.

Enzyme assay. The enzyme assay was carried out at 30°C for 3 to 12 h in a 100- μ l volume of 20 mM potassium phosphate (pH 7.4), 0.05 mM CoCl₂, 2 mM KF, 1 mM NAD⁺, 5 mM sedoheptulose 7-phosphate, and 50 μ l of protein solution (2.4 mg/ml protein). The reaction progress was monitored by thin-layer chromatography analysis. The reaction mixture was lyophilized and the reaction products were extracted with methanol. This extract was then dried and a few drops of SIGMA-SIL-A (SIGMA) were added. The solvent was removed in a flow of argon gas and the products were reextracted with *n*-hexane and injected for gas chromatography-mass spectroscopy (GC-MS) (Hewlett Packard 5890 series II gas chromatograph).

Nucleotide sequence accession number. The DNA and deduced protein sequences reported in this paper have been deposited in GenBank under accession number AY753181.

RESULTS

S. hygroscopicus 5008 contains a homologue of the *acbC* gene required for acarbose biosynthesis in *Actinoplanes*. Probing a Southern transfer of BamHI-digested genomic DNA of 5008 with the labeled *acbC* gene (a 1,264-bp NdeI-EcoRI fragment carrying a gene involved in the cyclization of D-sedoheptulose 7-phosphate to 2-*epi*-5-*epi*-valiolone of the acarbose biosynthetic pathway) of *Actinoplanes* sp. strain SE50/110 gave a weak signal at ca. 6 kb at low stringency in $6 \times SSC$ ($1 \times SSC$ is 0.15 M NaCl plus 0.015 M sodium citrate) and $65^{\circ}C$ (data not shown). To isolate the hybridizing fragment, further hybridization with the same probe in a pHZ1358 library was carried out with the same stringency. Six of the 39 initial isolates were confirmed positive by successive hybridization experiments. Five (4G8, 3G8, 17F2, 20E1, and 13G5, Fig. 2) out of the six positive overlapping cosmids shared a common 6-kb fragment hybridizing to the above-mentioned probe, while the sixth cosmid (15H4) gave a hybridization signal to a fragment of only about 3 kb (Fig. 2).

The BamHI digestion patterns of the six cosmids resulted in a contig spanning ca. 70 kb, without apparent genomic rearrangement. The different hybridization signal originating from BamHI-digested 15H4 was found to have resulted from the regeneration of a BamHI (designated B' in Fig. 2) site between the cloning site (BamHI) of the vector and an accidental MboI site of the insert during library construction, as this fragment was found to lie at the very end of the cloned fragment in cosmid 15H4.

Cosmid 3G8 contains genes involved in validamycin biosynthesis. One of the six pHZ1358-derived (26) bifunctional cosmids, 3G8 (Fig. 2), carrying a *tsr* gene suitable for selection in *Streptomyces* and a 34.2-kb insert under the control of pIJ101 origin of replication (6), was proven to be extremely unstable (ca. 98% loss after one round of nonselective growth on SFM medium) in strain 5008. For targeted gene replacement, ca. 30 kb of the strain 5008 DNA insert containing the *acbC* homologue in cosmid 3G8 was replaced by a 1.4-kb apramycin resistance (Apr^r) determinant, *aac(3)IV*, which resulted in pHZ2236 for subsequent conjugation.

pHZ2236 was transferred by conjugation from *E. coli* ET12567(pUZ8002) into strain 5008. About 10^{-8} exconjugants per donor were obtained which were initially selected to be Apr^r. Surprisingly, all four randomly selected exconjugants were found to be sensitive to thiostrepton. A Southern transfer of total DNA (Fig. 3B) from the four Apr^r Thio^s exconjugants (YU-1-1 to YU-1-4) together with wild-type 5008 was probed with the labeled 5.6-kb insert from pHZ2236 (Fig. 3A). As



FIG. 3. Replacement of a 30-kb region containing the *acbC* homologue by *aac(3)IV* in strain 5008. (A) Schematic representation of the replacement of the 30 kb of DNA mediated by 2.1-kb genomic fragments flanking both sides of the 1.4-kb *aac(3)IV* apramycin resistance determinant in pHZ2236. The mutants generated by double crossover (YU-1-1 to YU-1-4) had a fusion of the 10-kb leftward BamHI fragment with the BgIII end of the 1.4-kb *aac(3)IV* to form an 11.4-kb new BamHI fragment, but keep the rightward 7-kb fragment unchanged. (B) Southern hybridization using the α -[³²P]dCTP-labeled 5.6 (2.1 + 1.4 + 2.1)-kb insert from pHZ2236 as the probe after genomic DNAs of the wild-type 5008 and its derivatives (YU-1-1 to YU-1-4) were digested with BamHI. (C) HPLC analysis demonstrating that validamycin A is produced by wild-type strain 5008, but not by YU-1.

expected, the ca. 30-kb fragment in the 5008 chromosome was found to be replaced by a 1.4-kb fragment in the YU-1 mutants, resulting in a fusion of the 10-kb leftward BamHI fragment with the BgIII end of the 1.4-kb aac(3)IV to form a new 11.4-kb BamHI fragment (Fig. 3A), which is distinguishable from the 10-kb BamHI fragment of the wild-type 5008 in Fig. 3B.

All four mutants were tested for their ability to inhibit the growth of *Pellicularia sasakii*, a plant pathogen causing rice sheath blight disease. While *P. sasakii* stopped growing on agar plates containing the fermentation supernatant of strain 5008 (as a positive control), the fungus continued to grow on plates

containing the fermentation supernatants of each of the four candidate strains (YU-1-1 to YU-1-4). HPLC analysis revealed that the mutant candidates did not produce validamycin like the wild-type strain. Unlike with the wild-type strain 5008, no peak corresponding to validamycin A (retention time of 9.5 min) was found in samples obtained from the individual mutant candidates (Fig. 3C). This is consistent with the presumption that genes essential for validamycin biosynthesis including the *acbC* homologue have been deleted.

Sequencing analysis of a DNA fragment including the *acbC* **homologue.** The common 6-kb BamHI fragment shared by the

ValA AcbC AroBBs AroBEc AromAn	10 MTMTKQSSLSPGSRL3 VSGVETV(20 ZD YT T QD GAAX ZV HADAHRD SY 	30 WAVSALKEVS YQVRAQKQIT ILHVQTASSS RIVVTLGERS WPTKISILGR	40 YDVVVQPRILD YDVRFRDDVFG YPVFIGQGIRK YPITIASGIFN ESIIADF <mark>GL</mark> YR	50 PANPATADA HDSTDULEA KACELUTSL EPASFUPLK NYVAKDLIS	60 LSSGTTPARRI GADGAGSRRRI NRPLTRI SGEQV DCSSTTY	70 LIVIDATVRS TVVVDSAVDA IEVTDEEVDR IEVTDEEVDR IEVTDETLAP 7EVTDTNIGS	80 LYGEQLAAYU LYGSRIREYF LYGDEMLHLU LYLDKVRGVU LYLDKVRGVU IYTPSFEEAFI	90 AGHDV IHHGI JEKWP SQAGV RKRAA
ValA AcbC AroBBs AroBEc AromAn	100 EFHLCVIDAN DHSILVMRV -VKKVTVPS NVDSVILPD EITPSPRLLIYNRPP	110 HESAKVMETVI HETVKDFDTA(HEQAKSMDMY) HEQAKSMDMY HEQYSKSLAVLI	120 FEVVD AMDAF GRIVA AMDAF IKLQSEAIR- DIVFTALLQ- ADIEDWALSQ	130 GVPRRHA-PVL GLARRRE-PM -FHMDRSSCI -KPHGRDTTLV NPPCGRDTVVI	140 AMGGGVI TD VVGGGVI MD AFGGGVVGD ALGGGVVGD ALGGGVIGD	150 IVGLAASLYR VAGLVASLYR LAGFVAATFM LTGFAAASYO LTGFVASTVA	160 RATPYVRIPT ARHAVLRVPT RGIDFIQMPT RGVRFIQVPT RGVRYVQVPT	170 TLIGMIDAGI TLVGLIDA-VS TLLAH-DSAVI TLLSQVDSSVI TLLAMVDSSI	180 FAKTG SREDR GGKVA GGKTA GGKTA 2/3
ValA AcbC AroBBs AroBEc AromAn	190 VNFREHKARLGTYHPS VNFNGHKEPAGYVRP VNFNGHKEPAGYVRP VNHPLGKALIGAFY() IDTPLGKALIGAFY() 2	SSLTUTDP GET SSLTUTDP GET ADL TULDRRET RAAVLYD TDET RASVVVDLD G TKIYTDLEF	210 ATTIDARHIR ATTIDARHIS ATTIDARHIS RSLPEKETR KITIPARELA ETTIPARELA	220 NGLAEILRVAL NGLAEULKIAL SGLAEVIKHAE SGLAEVIKYGI MGMAEVIKIAA 1/4 4	UNDAELFDL IKDAELFQL IKDAELFQL ILDGAFFNW ISSEEFTA	240 LEGHGASUVE(LERHGRVLIE) LLN-IHSURD LEENLDAULRI LEENAETILK	250 JRMQ-PGEGG ERFQGYPEPV ITN LDG	260 TGGAAI TGPPS(DQL) PAM HRFEGTEEILJ	270 TVLR SPCAR NDMIF AYCIR KARIL
ValA AcbC AroBBs AroBEc AromAn	280 RAVQGMLEELQPNLW HPWHAGGTRPNLW KGISIKASVVQQDEK RCCELKAEVVAADER ASARHKAYVVSADER 3 3	290 BHOTARREVOF SREERSVDY ECTRAYANF TOTRATANF GCERNIARN 3 2 380	300 CHSESPSVEM CHTESPTIEM CHTEGHAVEA CHTCGHAVEA CHTCGHATEA CHATEA CHATEA 1 1 390	310 AALP-ELLHGE RALP-ALLHGE EYGYGQITHGD EMGYGNWLHGE ILTP-QILHGE 1 400	320 AVCIDIALS AVCVDIALT AVAL SIQFA AVAL SIQFA AVALSIVMA CVALSIVKE 410	330 SVLAHHRCLU TVLAYRRCLU LYISEKT-VG ARTSERLCOF: AELARHLCIU	340 IFAELGRVLD DVAQRDRIFA CEMDRKRLVS SSAETQRIIT KGVAVSRIVK 430	350 VMRLUHLPUL VMTALGLPTWI WLKSLGYPSQI LUKRAGLPVN(CLAAYGLPTSI	360 IR IR IR IR IR
ValA AcbC AroBBs AroBEc AromAn	VCTPDLM KETETSVII REMSAQAXI IRKLTAGKHCSVDQ	RAALAD TVKH EAAL OD TVRH LNRMMNDKK LPHMLRDKKVI IFNMALDKKNI	RDGWQHMPICP RDGWQRLPLP RGGKIQFIVL LAGEMRLICP DGPKKKIVL	RGIGDAVFVND VGIGGVTFVND NELGKVADHTF LAIGKSEVRSG SAIGTPYETRA	VTQREIEAA VTAG SRNELESWL VSHELVL SVVANEDIR	LLTLAERDRVI RAGRPR NKWRLEETS NADADCQSA VVLAPSI	PRWRALHGAV	DMG¥ 	

FIG. 4. Alignment of ValA with AcbC and three AroB proteins. Deduced amino acid sequences are from the following organisms: AcbC, *Actinoplanes* sp. (Y18523.3); AroBBs, *Bacillus subtilis* (M80245); AroBEc, *E. coli* (X03867); and AromAn, *Emericella* (formerly *Aspergillus*) *nidulans* (395-amino-acid DHQS domain at the N terminus of the pentafunctional AROM protein; X05204). A functional attribution of the amino acid residues indicated with black arrows, based on the analysis of the three-dimensional structure of the dehydroquinate synthase (DHQS) domain of *E. nidulans* (4), is given below the alignment by the following code: $1 = Co^{2+}$ binding (Zn²⁺ in the fungal protein instead); 2 = heptulose phosphate group binding; 3 = C-1 hydroxyl fixation; and 4 = C-4 hydroxyl fixation.

five cosmids (4G8, 3G8, 17F2, 20E1, and 13G5, Fig. 2) including the *acbC* homologue was cloned into pBluescript II SK(+) and sequenced. The overall G+C content of the sequenced region was 67.9%, lower than that of *S. coelicolor* A3(2), which showed an overall G+C content of 72.1%. FramePlot (11) analysis revealed three open reading frames (*valA*, *valB*, and *valC*) transcribed in the same direction, with *valA* separated from *valB* by 5 bp, while *valB* and *valC* overlap by 3 bp, suggesting that they are transcribed into one polycistronic mRNA (Fig. 2).

The *valA* gene seems to encode a polypeptide of 412 amino acids in length, with a putative ribosome binding site (GTGA) 10 bp preceding the putative translational start codon (ATG). The nucleotide sequence of *valA* has 59.5% identity with the *Actinoplanes acbC* gene, while the deduced ValA protein has 48% identity with the AcbC protein (25) (Fig. 4). The ValA protein also showed significant similarity (37% identity) to the

AroB protein from *Emericella nidulans* (Fig. 4), which is known to be responsible for the cyclization of 3-deoxy-D-arabino-hep-tulosonate 7-phosphate (DAHP) to dehydroquinate (4).

The deduced amino acid sequence (373 amino acids) of ValB shows 33% identity with GlgC, a glucose-1-phosphate adenylyltransferase isolated from *Bacillus halodurans* C-125 (8). ValC (351 amino acids) shows 30% identity to AcbM, the 2-*epi*-5-*epi*-valiolone 7-kinase from the acarbose biosynthetic gene cluster, whose demonstrated function is to phosphorylate 2-*epi*-5-*epi*-valiolone to form 2-*epi*-5-*epi*-valiolone 7-phosphate. Additionally, ValC also shows weaker homology with glucokinase from a *Bacillus* species (29% identity and 43% similarity).

There is an incomplete open reading frame (tentatively designated ORF1) at the 5' end of the fragment, which is transcribed in the opposite direction and shows 31% identity to the N-terminal amino acids of dTDP-4-dehydrorhamnose reductase, RmlD, whose known function is to reduce dTDP-6-deoxy-



FIG. 5. Inactivation of *valA* of the validamycin biosynthetic gene cluster. (A) Schematic representation of the replacement of a 563-bp internal fragment of *valA* with the 1.4-kb *aac(3)IV*. In shuttle plasmid pJTU519, *aac(3)IV* was inserted between 1.3-kb and 1.5-kb genomic fragments originally flanking the deleted 563-bp region. While wild-type 5008 should give a 1.2-kb PCR-amplified product, mutant JXH-1 should yield a 2.1-kb product using a pair of primers (ValA-F and ValA-R) designed for amplification of full-length *valA*. (B) PCR analysis of wild-type 5008 and mutant JXH-1. (C) HPLC comparison between 5008 and JXH-1. The peak corresponding to validamycin A is absent from mutant JXH-1.

L-xylo-4-hexulose to dTDP- L-rhamnose in *Geobacillus stearo*thermophilus (19).

DNA replacement in *valA* **is abolished validamycin biosynthesis.** Direct evidence for the involvement of *valA* in the biosynthesis of validamycin came from the replacement of a 563-bp DNA fragment internal to *valA* with *aac(3)IV* (Fig. 5A). This was performed by using a pHZ1358-derived plasmid (pJTU519, detailed in Materials and Methods), in which *aac(3)IV* (apramycin resistance gene) was sandwiched between sequences of 1.33 kb flanking to the left, and 1.5 kb flanking to the right of the 563-bp DNA to be deleted (Fig. 5A). JXH-1, a 5008 derivative, was obtained after introduction of pJTU519 into wild-type strain 5008 by conjugation from *E. coli* ET12567(pUZ8002), initial selection by thiostrepton, and further screening for the Thio^s Apr^r phenotype. Total DNA from the two independent Thio^s Apr^r exconjugants (JXH-1-1 and JXH-1-2) and from the wild-type strain 5008 was used as template for PCR amplification using two oligonucleotide primers (ValA-F and ValA-R) (Fig. 5B).

The 5008 DNA gave a 1.2-kb PCR product, while both JXH-1-1 and JXH-1-2 gave an expected 2.1-kb PCR product (Fig. 5B), which confirmed that a 563-bp DNA fragment internal to *valA* (Fig. 5A) has been removed from the chromosome of these mutants. No inhibition of *Pellicularia sasakii* could be detected in the bioassay, as in the case of YU-1 reported above, and no peak corresponding to validamycin A could be detected in the JXH-1-1 sample by HPLC analysis (Fig. 5C) as opposed to that of 5008, confirming the complete loss of validamycin production in JXH-1-1.

Characterization of ValA activity using heterologously overexpressed protein. In order to confirm the function of its gene product as a 2-epi-5-epi-valiolone synthase, valA was heterologously expressed in *E. coli*. A 1.24-kb DNA fragment containing the valA gene was amplified from cosmid 3G8 by PCR,



FIG. 6. (A) Sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis of the His₆-tagged ValA protein. Lanes: 1, molecular weight markers; 2, soluble protein of cell extract of *E. coli* BL21Gold(DE3)pLysS/*valA* before induction with IPTG; 3, total protein of cell extract of *E. coli* BL21Gold(DE3)pLysS/*valA* after induction with IPTG; 5, purified His₆-tagged ValA. (B) Thin-layer chromatography analyses of ValA assay (solvent system, *n*-butanol:ethanol:H₂O, 9:7:4). Lane 1, ValA without substrate; lane 2, boiled ValA with sedoheptulose 7-phosphate; lane 3, ValA with sedoheptulose 7-phosphate; lane 4, 2-*epi-5-epi*-valiolone.

introducing BgIII and NdeI restriction sites with the forward primer and an EcoRI site with the reverse primer. The PCR product was subcloned into the expression vector pRSET-B as a BgIII/EcoRI fragment, transformed into *E. coli* XL-1-Blue. The correct plasmids were subsequently transformed into *E. coli* BL21Gold(DE3)pLysS. Expression of *valA* under the control of the T7 promoter was induced by isopropyl- β -D-thiogalactopyranoside (IPTG), which gave rise to a 48-kDa soluble polyhistidine-tagged protein. Affinity purification on a Ni-nitrilotriacetic acid spin column (QIAGEN) or a BD TALON column gave a protein that was >80% pure as judged by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (Fig. 6A).

To test the catalytic activity of ValA, the enzymatic reaction was carried out using sedoheptulose 7-phosphate as the substrate under reaction conditions used previously for the AcbC protein of acarbose biosynthesis (25). The reaction extracted with methanol gave rise to a product which has the same R_f value as authentic 2-epi-5-epi-valiolone on thin-layer chromatography (Fig. 6B). On the other hand, incubation with cell extracts of *E. coli* harboring the empty pRSET-B vector gave no product.

The product was extracted from the lyophilized reaction mixture by methanol, converted to its trimethylsilylated derivative, and analyzed by GC-MS (Fig. 7). An isotopically labeled authentic sample, 2-epi-5-epi-[6-²H2]valiolone, chemically synthesized from D-mannose (25) was used for comparison (Fig. 7A). The enzyme product was detected as a tetratrimethylsilyl derivative of 2-epi-5-epi-valiolone [m/z 480 (M+)] with major fragment ions at m/z 335, 276, 217, 147, and 73 (Fig. 7D). This fragmentation pattern is consistent with that of the authentic sample, which showed m/z 482 (M+), 335, 278, 217, 147, and 73 (Fig. 7C).

DISCUSSION

Considerable effort has been made in our laboratories during the last few years to clone biosynthetic genes for the aminocyclitol antibiotic validamycin, which is commercially produced on a large scale in China and some other eastern Asian countries and is widely used for the protection of rice seedlings against fungal sheath blight. Genetic manipulation of the structural and/or regulatory genes is expected to be of great help for strain improvement, e.g., to increase yield or the relative abundance of the validamycin A component in the fermentation broth, and possibly to make new validamycin derivatives.

A first effort by heterologous expression in *Streptomyces lividans* 66, based on the proposed biosynthetic pathway (7) that implied that the validamycin gene cluster may possess a limited number of genes, failed in an initial trial. A second attempt using radioactively labeled *strD* encoding dTDP-glucose synthase of the streptomycin biosynthetic gene cluster of *Streptomyces griseus* as a probe also yielded no signal, which suggests that the activation of glucose in validamycin biosynthesis is catalyzed by an enzyme different from StrD, which seems to be specific for 6-deoxyhexose pathways.

The success of using the *acbC* gene from the acarbose cluster of *Actinoplanes* to probe for the validamycin biosynthetic gene cluster was not surprising, as both compounds contain the same valienamine moiety in their structures, whose initial biosynthetic step involves cyclization of D-sedoheptulose 7-phosphate to form 2-epi-5-epi-valionone. The significant sequence homologies between ValA and ValC of the validamycin pathway and AcbC and AcbM (40) of the acarbose pathway strongly support the idea that they have similar functions. This suggests that 2-epi-5-epi-valiolone in validamycin biosynthesis has the same fate of being phosphorylated (by ValC) as was demonstrated in acarbose biosynthesis (29).

It was proposed that all of the intermediates from 2-epi-5epi-valiolone to valienone in the acarbose biosynthetic pathway are phosphorylated (29), which explains the lack of incorporation of the nonphosphorylated putative intermediates, such as 5-epi-valiolone and valienone. On the contrary, nonphosphorylated 5-epi-valiolone, valienone, and validone were found to be efficiently incorporated into validamycin A (7). If ValC has a role in phosphorylating the intermediates in the validamycin pathway similar to that of AcbM in acarbose biosynthesis, its substrate specificity or catalytic ability to phosphorylate all of





the cyclitol intermediates, including 2-epi-5-epi-valiolone, remains to be explored.

Both ValA and AcbC show significant similarities to AroBrelated DHQS proteins from diverse organisms (4, 8, 17), whose catalytic function is known to be cyclization of DAHP to dehydroquinate. Based on the analysis of the three-dimensional structure of the DHQS domain of the functional AroM protein of the filamentous fungus Emericella nidulans, a total of 13 amino acid residues were identified to be important for catalysis and as being involved in Zn^{2+} binding (Co^{2+} in bacteria instead; indicated as 1 in Fig. 4), heptulose phosphate group binding (indicated as 2 in Fig. 4), C-1 hydroxyl fixation (indicated as 3 in Fig. 4), or C-4 hydroxyl fixation (indicated as 4 in Fig. 4) (4). In ValA, three of the four identified residues for Co^{2+} binding (1), three of the four for heptulose phosphate group binding (2), two of the three for C-1 hydroxyl fixation (3), and all three for C-4 hydroxyl fixation (4), are conserved. Therefore, ValA seems to be more related to AroB proteins than AcbC.

Preceding *valC* is a cotranscribed gene, *valB*, encoding a putative adenyltransferase (ValB). Conceivably, this activity could be involved in the conversion of glucose 1-phosphate, possibly from primary metabolism, into dTDP-glucose. Incorporation of activated glucose has been proven through feeding experiments with validoxylamine A to be the final step in validamycin biosynthesis (14). Alternatively, ValB may be involved in the activation of one of the cyclitol intermediates, e.g., 1-*epi*-valienol 1-phosphate, to its nucleotide derivative, setting the stage for the coupling reaction that leads to a pseudodisaccharide intermediate.

The combination of the results of the previous feeding experiments (7) with the genetic and biochemical information obtained, especially the results of the in vivo gene inactivation and in vitro enzymatic characterization of ValA, strongly suggests that the identified genes are involved in validamycin biosynthesis. From the overlapping cosmid contig we know that the flanking DNA to the left and right of the 6-kb sequenced region covering the complete valA, valB, and valC genes extends to 29 kb and 35 kb, respectively, likely to cover the complete set of genes necessary for validamycin formation. We can thus expect a detailed understanding of the biosynthesis of validamycin, which is critical for more targeted strain improvement or generating novel validamycin derivatives by combined genetic and biochemical approaches. This will become possible when the entire gene cluster has been completely sequenced and the genes have been individually characterized, work that is now in progress.

ACKNOWLEDGMENTS

We thank T. Koch and G. Wei for preliminary experiments. We thank David A. Hopwood, Tobias Kieser, Keith F. Chater, Mervyn J. Bibb, Mark Buttner, and Wolfgang Piepersberg for gifts of plasmid, phage, and the *strDE* probe.

This work received 973 and 863 Funds from the Ministry of Science and Technology, the National Science Foundation of China, the Ph.D. Training Fund from the Ministry of Education, and the Shanghai Municipal Council of Science and Technology. Work at Oregon State University and the University of Washington was supported by NIH grants RAI061528A and AI20264, respectively.

REFERENCES

 Altschul, S. F., W. Gish, W. Miller, E. W. Myers, and D. J. Lipman. 1990. Basic local alignment search tool. J. Mol. Biol. 215:403–410.

- Bentley, S. D., K. F. Chater, A. M. Cerdeno-Tarraga, G. L. Challis, N. R. Thomson, K. D. James, D. E. Harris, M. A. Quail, H. Kieser, D. Harper, A. Bateman, S. Brown, G. Chandra, C. W. Chen, M. Collins, A. Cronin, A. Fraser, A. Goble, J. Hidalgo, T. Hornsby, S. Howarth, C. H. Huang, T. Kieser, L. Larke, L. Murphy, K. Oliver, S. O'Neil, E. Rabbinowitsch, M. A. Rajandream, K. Rutherford, S. Rutter, K. Seeger, D. Saunders, S. Sharp, R. Squares, S. Squares, K. Taylor, T. Warren, A. Wietzorrek, J. Woodward, B. G. Barrell, J. Parkhill, and D. A. Hopwood. 2002. Complete genome sequence of the model actinomycete *Streptomyces coelicolor* A3(2). Nature 417:141–147.
- Borck, K., J. D. Beggs, W. J. Brammar, A. S. Hopkins, and N. E. Murray. 1976. The construction in vitro of transducing derivatives of phage lambda. Mol. Gen. Genet. 146:199–207.
- Carpenter, E. P., A. R. Hawkins, J. W. Frost, and K. A. Brown. 1998. Structure of dehydroquinate synthase reveals an active site capable of multistep catalysis. Nature 394:299–302.
- 5. Demain, A. L. 2000. Microbial biotechnology. Trends Biotechnol. 18:26-31.
- Deng, Z. X., T. Kieser, and D. A. Hopwood. 1988. "Strong incompatibility" between derivatives of the *Streptomyces* multicopy plasmid pIJ101. Mol. Gen. Genet. 214:286–294.
- Dong, H., T. Mahmud, I. Tornus, S. Lee, and H. G. Floss. 2001. Biosynthesis of the validamycins: identification of intermediates in the biosynthesis of validamycin A by *Streptomyces hygroscopicus var. limoneus*. J. Am. Chem. Soc. 123:2733–2742.
- Henner, D. J., L. Band, and H. Shimotsu. 1985. Nucleotide sequence of the Bacillus subtilis tryptophan operon. Gene 34:169–177.
- Hopwood, D. A., M. J. Bibb, K. F. Chater, T. Kieser, C. J. Bruton, H. M. Kieser, D. J. Lydiate, C. P. Smith, J. M. Ward, and H. Schrempf. 1985. Genetic manipulation of *Streptomyces*-a laboratory manual. The John Innes Foundation, Norwich, Conn.
- Horii, S., H. Fukase, T. Matsuo, Y. Kameda, N. Asano, and K. Matsui. 1986. Synthesis and alpha-D-glucosidase inhibitory activity of N-substituted valiolamine derivatives as potential oral antidiabetic agents. J. Med. Chem. 29: 1038–1046.
- Ishikawa, J., and K. Hotta. 1999. FramePlot: a new implementation of the frame analysis for predicting protein-coding regions in bacterial DNA with a high G + C content. FEMS Microbiol. Lett. 174:251–253.
- 12. Janssen, G. R., and M. J. Bibb. 1993. Derivatives of pUC18 that have BgIII sites flanking a modified multiple cloning site and that retain the ability to identify recombinant clones by visual screening of *Escherichia coli* colonies. Gene **124**:133–134.
- Kameda, Y., N. Asano, T. Yamaguchi, K. Matsui, S. Horii, and H. Fukase. 1986. Validamycin G and validoxylamine G, new members of the validamycins. J. Antibiot. (Tokyo) 39:1491–1494.
- Kameda, Y., S. Horii, and T. Yamano. 1975. Microbial transformation of validamycins. J. Antibiot. (Tokyo) 28:298–306.
- Kieser, T., M. J. Bibb, K. F. Chater, M. J. Butter, and D. A. Hopwood. 2000. Practical *Streptomyces* genetics. a laboratory manual. John Innes Foundation, Norwich, United Kingdom.
- Mahmud, T. 2003. The C₇N aminocyclitol family of natural products. Nat. Prod. Rep. 20:137–166.
- Millar, G., and J. R. Coggins. 1986. The complete amino acid sequence of 3-dehydroquinate synthase of *Escherichia coli* K12. FEBS Lett. 200:11–17.
- Moffatt, B. A., and F. W. Studier. 1987. T7 lysozyme inhibits transcription by T7 RNA polymerase. Cell 49:221–227.
- Novotny, R., C. Schaffer, J. Strauss, and P. Messner. 2004. S-layer glycanspecific loci on the chromosome of *Geobacillus stearothermophilus* NRS 2004/3a and dTDP-L-rhamnose biosynthesis potential of G. stearothermophilus strains. Microbiology 150:953–965.
- Omura, S., H. Ikeda, J. Ishikawa, A. Hanamoto, C. Takahashi, M. Shinose, Y. Takahashi, H. Horikawa, H. Nakazawa, T. Osonoe, H. Kikuchi, T. Shiba, Y. Sakaki, and M. Hattori. 2001. Genome sequence of an industrial microorganism *Streptomyces averniilis*: deducing the ability of producing secondary metabolites. Proc. Natl. Acad. Sci. USA 98:12215–12220.
- Paget, M. S., L. Chamberlin, A. Atrih, S. J. Foster, and M. J. Buttner. 1999. Evidence that the extracytoplasmic function sigma factor sigmaE is required for normal cell wall structure in *Streptomyces coelicolor* A3(2). J. Bacteriol. 181:204–211.
- Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
- Shibata, M., M. Uyeda, and K. Mori. 1981. Stimulation of the extension of validamycin-inhibited hyphae by the hyphal extension factor present in Rhizoctonia solani. J. Antibiot. (Tokyo) 34:447–451.
- Stockmann, M., and W. Piepersberg. 1992. Gene probes for the detection of 6-deoxyhexose metabolism in secondary metabolite-producing streptomycetes. FEMS Microbiol. Lett. 69:185–189.
- Stratmann, A., T. Mahmud, S. Lee, J. Distler, H. G. Floss, and W. Piepersberg. 1999. The AcbC protein from Actinoplanes species is a C7-cyclitol synthase related to 3-dehydroquinate synthases and is involved in the biosynthesis of the alpha-glucosidase inhibitor acarbose. J. Biol. Chem. 274: 10889–10896.

- Sun, Y., X. Zhou, J. Liu, K. Bao, G. Zhang, G. Tu, T. Kieser, and Z. Deng. 2002. 'Streptomyces nanchangensis', a producer of the insecticidal polyether antibiotic nanchangmycin and the antiparasitic macrolide meilingmycin, contains multiple polyketide gene clusters. Microbiology 148:361–371.
- Xia, T. H., and R. S. Jiao. 1986. Studies on glutamine synthetase from Streptomyces hygroscopicus var. jinggangensis. Sci. Sin. B 29:379–388.
- Yanisch-Perron, C., J. Vieira, and J. Messing. 1985. Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. Gene 33:103–119.
- 29. Zhang, C. S., A. Stratmann, O. Block, R. Bruckner, M. Podeschwa, H. J.

Altenbach, U. F. Wehmeier, and W. Piepersberg. 2002. Biosynthesis of the C(7)-cyclitol moiety of acarbose in Actinoplanes species SE50/110. 7-O-phosphorylation of the initial cyclitol precursor leads to proposal of a new biosynthetic pathway. J. Biol. Chem. **277**:22853–22862.

- Zhou, X., X He, A Li, T. Kieser, and Z. Deng. 2004. The Streptomyces lividans 66 chromosome has a genomic island which is not present in Streptomyces coelicolor A3(2). Appl. Environ. Microbiol. 70:7110–7118.
- Zvenigorodskii, V. I., and N. D. Lomovskaya. 1974. The induction of prophage by a virulent mutant of actinophage φC31 of *Streptomyces coelicolor* A3(2). Sov. Genet. 8:629–634.